Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men. / Hostrup, Morten; Knudsen, Jakob Grunnet; Maag Kristensen, Caroline; Jessen, Søren; Pilegaard, Henriette; Bangsbo, Jens.
I: Scandinavian Journal of Medicine & Science in Sports, Bind 32, Nr. 7, 2022, s. 1099-1108.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men
AU - Hostrup, Morten
AU - Knudsen, Jakob Grunnet
AU - Maag Kristensen, Caroline
AU - Jessen, Søren
AU - Pilegaard, Henriette
AU - Bangsbo, Jens
N1 - This article is protected by copyright. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Objective: Several tissues produce and release interleukin-6 (IL-6) in response to beta2-adrenergic stimulation with selective agonists (beta2-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta2-agonists regulate skeletal muscle production and release of IL-6 in humans, in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta2-agonist salbutamol in lean young men at rest and in recovery from resistance exercise.Design: The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.Results: Average leg IL-6 release was 1.7-fold higher (p=0.01) for salbutamol than placebo, being 138±76 and 79±66 pg∙min-1 (mean±SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5 and 1.7-fold higher (p=0.001) for salbutamol than placebo ½ and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-α mRNA.Conclusions: Beta2-adrenergic stimulation with high doses of the selective beta2-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise and increases muscle IL-6 release in lean individuals.
AB - Objective: Several tissues produce and release interleukin-6 (IL-6) in response to beta2-adrenergic stimulation with selective agonists (beta2-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta2-agonists regulate skeletal muscle production and release of IL-6 in humans, in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta2-agonist salbutamol in lean young men at rest and in recovery from resistance exercise.Design: The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.Results: Average leg IL-6 release was 1.7-fold higher (p=0.01) for salbutamol than placebo, being 138±76 and 79±66 pg∙min-1 (mean±SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5 and 1.7-fold higher (p=0.001) for salbutamol than placebo ½ and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-α mRNA.Conclusions: Beta2-adrenergic stimulation with high doses of the selective beta2-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise and increases muscle IL-6 release in lean individuals.
KW - Faculty of Science
KW - Beta-adrenoceptor
KW - Beta2-adrenoceptor
KW - Beta2
KW - SABA
KW - Cytokine
U2 - 10.1111/sms.14171
DO - 10.1111/sms.14171
M3 - Journal article
C2 - 35460295
VL - 32
SP - 1099
EP - 1108
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
SN - 0905-7188
IS - 7
ER -
ID: 304056474